Upgrade Your Browser
We no longer support this version of your browser.
We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.
Return to the course you were viewing
SGLT2 inhibitor (empagliflozin, etc) risks will be back in the spotlight...due to recent label changes.
These meds are getting more use now that most have proven CV benefits...despite usually costing about $500/month.
Be familiar with how to manage SGLT2 inhibitor risks.
Prescriber's Letter includes:
Already a subscriber? Log in
Volume pricing available. Get a quote